{
  "trial_id": "NCT01447524",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "diet or oral hypoglycaemic agents",
      "label": "met",
      "evidence": "treatment with corticosteroid and cyclophosphamides"
    },
    {
      "criterion": "morbid obesity (BMI > 40kg/m2)",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "good metabolic control (HbA1C <7.5%)",
      "label": "not_met",
      "evidence": "Hgb: 13 g/dl, HbA1C not mentioned"
    }
  ],
  "exclusion": [
    {
      "criterion": "treatment with GLP-1 agonists, DPP-4 inhibitors, insulin",
      "label": "met",
      "evidence": "treatment with corticosteroid and cyclophosphamides"
    },
    {
      "criterion": "serum creatinine >150 \u00b5mol/l",
      "label": "unknown",
      "evidence": ""
    }
  ],
  "notes": "Patient has Wegener's granulomatosis, being treated with corticosteroids and cyclophosphamides. His Birmingham Vasculitis Activity Score (BVAS) is above 4.",
  "_meta": {
    "topic_id": "54",
    "trial_id": "NCT01447524",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}